CELEX: 62015CA0138
Language: en
Date: 2016-03-03 00:00:00
Title: Case C-138/15 P: Judgment of the Court (Sixth Chamber) of 3 March 2016 — Teva Pharma BV, Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA), European Commission (Appeal — Orphan medicinal products — Regulation (EC) No 141/2000 — Regulation (EC) No 847/2000 — Refusal to grant marketing authorisation for the generic version of the orphan medicinal product ‘imatinib mesylate’)

2.5.2016   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 156/16
            
         Judgment of the Court (Sixth Chamber) of 3 March 2016 — Teva Pharma BV, Teva Pharmaceuticals Europe BV v European Medicines Agency (EMA), European Commission
   (Case C-138/15 P) (1)
   
   ((Appeal - Orphan medicinal products - Regulation (EC) No 141/2000 - Regulation (EC) No 847/2000 - Refusal to grant marketing authorisation for the generic version of the orphan medicinal product ‘imatinib mesylate’))
   (2016/C 156/22)
   Language of the case: English
   
      Parties
   
   
      Appellants: Teva Pharma BV, Teva Pharmaceuticals Europe BV (represented by: K. Bacon QC, E. Mackenzie, Barrister, and G. Morgan, Solicitor)
   
      Other parties to the proceedings: European Medicines Agency (EMA) (represented by: N. Rampal Olmedo, M. Tovar Gomis, S. Marino and T. Jabłoński, acting as Agents), European Commission (represented by: A. Sipos and M. Šimerdová, acting as Agents)
   
      Operative part of the judgment
   
   The Court:
   
               1.
            
            
               Dismisses the appeal.
            
         
               2.
            
            
               Orders Teva Pharma BV and Teva Pharmaceuticals Europe BV to bear their own costs and to pay the costs incurred by the European Medicines Agency (EMA).
            
         
               3.
            
            
               Orders the European Commission to bear its own costs.
            
         
      (1)  OJ C 190, 8.6.2015.